Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
berobenatide
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
Berobenatide (PF-08653944) is a long-acting oxyntomodulin (OXM) analog developed by Pfizer for the treatment of obesity and type 2 diabetes. It functions as a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). By activating GLP-1R, the drug promotes satiety and slows gastric emptying, while GCGR activation is intended to increase energy expenditure and improve metabolic rate. This dual mechanism aims to provide superior weight loss compared to selective GLP-1 receptor agonists. Berobenatide is designed for once-weekly subcutaneous administration and is currently undergoing Phase 3 clinical evaluation in specific regions, including China, for adults with overweight or obesity, including those with comorbid type 2 diabetes.
- Other names
- berobenatide
02
Targets
GCGR (Glucagon receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on berobenatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on berobenatide.